Table of contents
This is a summary of the European public assessment report (EPAR). Its purpose is to explain how the assessment done by the Committee for Medicinal Products for Veterinary Use (CVMP) on the basis of the documentation provided, led to the recommendations on the conditions of use.
This summary cannot replace a face-to-face discussion with your veterinarian. If you need more information about your animal’s medical condition or treatment, contact your veterinarian. If you want more information on the basis of the CVMP recommendations, read the scientific discussion (also part of the EPAR).
Meloxidyl : EPAR - Summary for the public (PDF/34.32 KB)
First published: 09/10/2009
Last updated: 06/09/2010
|Agency product number||
|International non-proprietary name (INN) or common name||
|Anatomical therapeutic chemical veterinary (ATCvet) codes||
This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see Generic and hybrid medicines.
Ceva Santé Animale
|Date of issue of marketing authorisation valid throughout the European Union||
10 avenue de la Ballastière
31/01/2019 Meloxidyl - EMEA/V/C/000115 - IA/0028/G
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Alleviation of inflammation and pain in both acute and chronic musculoskeletal disorders.
Reduction of post-operative pain and inflammation following orthopaedic and soft-tissue surgery.
Reduction of post-operative pain after ovariohysterectomy and minor soft-tissue surgery.
For use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs in cattle.
For use in diarrhoea in combination with oral rehydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle.
For adjunctive therapy in the treatment of acute mastitis, in combination with antibiotic therapy.
For use in non-infectious locomotor disorders to reduce the symptoms of lameness and inflammation.
For adjunctive therapy in the treatment of puerperal septicaemia and toxaemia (mastitis-metritis-agalactia syndrome) with appropriate antibiotic therapy.
For use in the alleviation of inflammation and relief of pain in both acute and chronic musculoskeletal disorders.
For the relief of pain associated with equine colic.
Meeting highlights from the Committee for Medicinal Products for Veterinary Use (CVMP) 7-9 December 202110/12/2021
Meeting highlights from the Committee for Medicinal Products for Veterinary Use (CVMP) 8-10 December 202011/12/2020